BioGaia ABBGLAF 100 Forward PE Ratio is 28.44 as of Jul. 04, 2026. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $12.51 (Fairly Valued). The stock has 5 warning signs investors should review. Among 407 Drug Manufacturers companies, BioGaia AB ranks worse than 75.43% on this metric.
BioGaia AB (OTCPK:BGLAF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
BioGaia AB Forward PE Ratio Related Terms
BioGaia AB Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB Forward PE Ratio Chart
BioGaia AB Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
24.13
25.52
BioGaia AB Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
24.13
23.89
24.56
22.22
25.52
26.32
BGLAF vs ZTS, UTHR: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
BioGaia AB (BGLAF) has a Forward PE Ratio of 28.44 as of Jul. 04, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BioGaia AB and its competitors. According to the industry distribution chart, BioGaia AB ranks #307 out of 407 companies in the Drug Manufacturers industry, placing it in the top 75.4%.
Is BioGaia AB's Forward PE Ratio too high?
BioGaia AB's current Forward PE Ratio is 28.44. The Drug Manufacturers industry median Forward PE Ratio is 17.37. BioGaia AB's value of 28.44 is 63.7% above this industry median. Based on the distribution chart, BioGaia AB ranks #307 out of 407 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #307 out of 407 companies for Forward PE Ratio. This places BioGaia AB in the lower half of its industry. The industry median Forward PE Ratio is 17.37. BioGaia AB's value of 28.44 is 63.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.37, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Forward PE Ratio of 28.44 is 63.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Forward PE Ratio is 28.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $12.51, compared to a current price of $12.20 — trading 2.5% below its estimated fair value. The current Forward PE Ratio is 28.44 and 63.7% above the Drug Manufacturers industry median of 17.37. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Forward PE Ratio is 28.44 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 2.5% below its estimated GF Value™ of $12.51.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
Forward PE Ratio: 28.44
GF Value™: $12.51 vs. price of $12.20 (2.5% below fair value)
Industry Position: 63.7% above the Drug Manufacturers median (#307 of 407)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 